Catalog No.
Product Name
Application
Product Information
Citations
-
Kappa Opioid Receptor Agonist
(±)-U-50488 is a selective agonist of the kappa opioid receptor. It has been shown to improve symptoms associated with status epilepticus, while exhibiting minimal impact on spontaneous seizure occurrences. This compound is valuable for research focused on epilepsy and its underlying mechanisms. -
Opioid Peptide
N-Acetyl-α-Endorphin is an acetylated form of the endogenous opioid peptide α-Endorphin, modified at the N-terminal. This compound primarily targets opioid receptors and exhibits significant analgesic properties. It is widely utilized in research focusing on pain management, addiction, and the modulation of neuronal signaling pathways associated with opioid activity. -
Opioid Receptor Agonist
BW443C is a selective agonist of opioid receptors, primarily targeting the mu-opioid receptor. This compound exhibits significant antinociceptive properties, making it valuable for research into pain management and analgesic therapies. BW443C is suitable for studying opioid receptor signaling pathways and evaluating the therapeutic potential of opioid agonists in various preclinical models. -
NOP Receptor Antagonist
UFP-101 is a selective and competitive antagonist of the NOP receptor, exhibiting a pKi of 10.24. It demonstrates greater than 3000-fold selectivity over delta, mu, and kappa opioid receptors. UFP-101 has been shown to produce antidepressant-like effects, making it a valuable tool for research into mood disorders and the role of NOP receptor signaling. -
Opioid Receptor Agonist
(rel)-RSD 921 is a potent κ-opioid receptor agonist known for its role in modulating pain and reward pathways. Research indicates that (rel)-RSD 921 has differential effects on appetite regulation, evidenced by similar food-inducing responses in both obese and lean Zucker rats, with lean rats exhibiting heightened sensitivity to its initial effects. This compound is valuable for studies focused on opioid signaling, appetite modulation, and related physiological responses. -
Ociceptin Receptor Antagonist
[Nphe1]Nociceptin(1-13)NH2 is a selective nociceptin receptor antagonist that exhibits competitive inhibition without any agonistic effects. It binds specifically to recombinant nociceptin receptors with a binding affinity (pKi) of 8.4 and effectively antagonizes nociceptin-induced inhibition of cyclic AMP accumulation in CHO cells (pA2=6.0). This compound shows promise for research applications related to pain modulation and the exploration of nociceptin signaling pathways. -
DOR Agonist
ADL-5747 hydrochloride is a selective and orally active agonist of the δ-opioid receptor (DOR). By activating DOR, it modulates pain management pathways, making it a valuable tool for investigating analgesic mechanisms. This compound is suitable for research focused on pain relief and the pharmacological implications of opioid receptors. -
MOR Activator
(RS)-Salsolinol hydrobromide is a μ-opioid receptor (MOR) activator derived from dopamine. It has been shown to reduce GABAergic transmission and increase the excitability of dopamine neurons, subsequently enhancing the sustained firing of neurons in the posterior ventral tegmental area (pVTA). This compound is useful in research applications investigating the modulation of dopaminergic signaling and its implications in various neurological conditions. -
δ1 Opioid Receptor Antagonist
BNTX (7-Benzylidenenaltrexone) is a selective antagonist of the δ1 opioid receptor. It effectively inhibits the antinociceptive effects mediated by spinal δ1 receptors while leaving the actions at δ2, μ, and κ opioid receptors unchanged at specific concentrations. This compound is useful in studying pain pathways and the role of δ1 receptors in analgesia, making it a valuable tool for research in pain management and opioid receptor pharmacology. -
δ-Opioid Receptor Antagonist
TRK-851 is a highly selective δ-opioid receptor antagonist, with a pA2 value of 8.84, indicating strong binding affinity. It exhibits over 100-fold selectivity for the δ-opioid receptor compared to μ or κ receptors. This compound demonstrates significant antitussive effects in preclinical models, particularly in capsaicin-induced cough assays. TRK-851 is suitable for research focused on the mechanisms of cough suppression and the role of δ-opioid receptors in pain modulation. -
κ-opioid Receptor Agonist
Spiradoline is a selective κ-opioid receptor (KOR) agonist, demonstrating a Ki of 8.6 nM in guinea pig models. With significantly higher Ki values for μ and δ receptors at 252 nM and 9400 nM, respectively, Spiradoline exhibits notable biological activities, including analgesic, diuretic, antiarrhythmic, antitussive, and neuroprotective effects. Its ability to effectively penetrate the blood-brain barrier makes it a valuable reagent for research in pain management and neurological studies. -
Opioid Receptor
Samidorphan isoquinoline dioxolane is an analog of cyclazocine that primarily targets opioid receptors. This compound exhibits significant opioid receptor binding activity, making it a valuable tool in the study of opioid pharmacology. Its unique structure and mechanism of action contribute to research applications in pain management, addiction studies, and the exploration of novel therapeutics related to the opioid system. -
Opioid Receptor Agonist
BU72 is a potent and long-acting agonist of the μ and κ opioid receptors, exhibiting partial agonist activity at δ opioid receptors with EC50 values of 0.054, 0.033, and 0.58 nM, respectively. This compound is characterized by its strong and sustained analgesic effects primarily mediated through μ opioid receptor activation. Additionally, BU72 has the capability to partially reverse morphine-induced analgesia, making it a valuable tool for research on opioid dependence and pain management strategies. -
KOR Agonist
(+)-U-50488 is a selective κ-opioid receptor (KOR) agonist exhibiting reduced potency compared to its enantiomer, (-)-Trans-(1S,2S)-U-50488. This compound is utilized in pharmacological research to investigate the role of KOR in pain modulation, mood disorders, and substance use disorders. Its ability to activate KOR provides a valuable tool for studying the physiological and pathophysiological functions of the opioid system. -
μ Opioid Receptor Antagonist
Acetalin-1 is a hexapeptide that acts as a μ opioid receptor antagonist, demonstrating high affinity for both μ and κ3 opioid receptors, while exhibiting weak affinity for κ1 receptors and no binding to κ2 receptors. Its inhibitory action on μ opioid receptors makes it a valuable tool for studying pain pathways and opioid receptor pharmacology. Acetalin-1's specificity and receptor binding profile support its use in research related to addiction, pain management, and opioid-related signaling pathways. -
KOR Agonist
(+)-U-50488 hydrochloride is a selective κ opioid receptor (KOR) agonist. It exhibits key biological activity in modulating pain pathways and is utilized in research focused on opioid receptor mechanisms. This compound is an important tool for studying the effects of KOR activation in various biological contexts. -
Opioid Receptor Agonist
β-Endorphin, equine is an endogenous opioid peptide that acts as a high-affinity agonist for μ and δ opioid receptors. It exhibits notable analgesic properties, making it valuable for research into pain modulation and opioid signaling pathways. This reagent is applicable in various in vitro and in vivo studies focused on opioid receptor function and related therapeutic applications in pain management and addiction research. -
μ-Opioid Receptor Antagonist
CTOP is a potent and highly selective μ-opioid receptor antagonist. It effectively counteracts the acute analgesic effects of morphine and mitigates hypermotility associated with opioid administration. Additionally, CTOP has been shown to enhance extracellular dopamine levels in the nucleus accumbens and dose-dependently increase locomotor activity, making it a valuable tool for research on opioid receptor functions and dopamine activity in the context of pain and addiction studies. -
MOR Agonist/σ1R Antagonist
EST73502 is a selective dual μ-opioid receptor (MOR) agonist and σ1 receptor (σ1R) antagonist, demonstrating effective blood-brain barrier penetration. With binding affinities (Kis) of 64 nM for MOR and 118 nM for σ1R, EST73502 exhibits notable antinociceptive properties. This compound is pertinent for research applications in pain management and neurological studies, allowing for the exploration of opioid receptor pathways and σ1R interactions. -
Opioid Receptor Antagonist
Axelopran is a potent opioid receptor antagonist that exhibits high affinity for human recombinant μ (pKi 9.8), δ (pKi 8.8) receptors, as well as the guinea pig κ receptor (pKi 9.9). This compound is primarily utilized in analgesic research and studies involving opioid receptor modulation. Its antagonistic properties make it valuable for investigating pain pathways and potential therapeutic applications in opioid overdose and addiction. -
Opioid Receptor Antagonist
Opioid receptor antagonist 1 is an Orvinol-based compound that acts as an opioid receptor antagonist. This reagent demonstrates effective antagonistic activity against the analgesic effects of Morphine, making it a valuable tool for investigating opioid signaling pathways and the mechanisms underlying opioid addiction and tolerance. Its applications extend to research focused on pain management and the development of new therapeutic strategies for opioid-related disorders. -
δ2-opioid Receptor Antagonist/TRPM7 Activator
Naltriben is a selective antagonist of the δ2-opioid receptor and an activator of TRPM7 channels. It has been shown to enhance migration and invasion of glioblastoma cells, making it a valuable tool for studying tumor biology. This compound is suited for research into neurological disorders and cancer mechanisms, providing insights into therapeutic approaches targeting these areas. -
Opioid Receptor Antagonist
Ondelopran is a non-selective opioid receptor antagonist that modulates opioid signaling pathways. This compound effectively inhibits dopamine release in the nucleus accumbens, counteracting the rewarding effects of alcohol consumption and reducing cravings associated with alcohol use disorder (AUD). Ondelopran is primarily utilized in research focused on addiction and the neurobiological mechanisms underlying substance use disorders. -
δ-opioid Receptor Agonist
(Rac)-SNC80 is a racemic compound that acts as a potent and selective agonist of the δ-opioid receptor, exhibiting a Ki value of 1.78 nM and an IC50 of 2.73 nM. This compound demonstrates significant antinociceptive, antihyperalgesic, and antidepressant-like effects, making it a valuable tool for research in pain management and mood disorders. Furthermore, (Rac)-SNC80 may have therapeutic potential for treating various headache disorders, facilitating studies focused on opioid receptor modulation and its implications in analgesia. -
Opioid Receptor
Naloxone-d5 is a deuterium-labeled derivative of Naloxone, a potent antagonist of opioid receptors. This compound selectively binds to opioid receptors, effectively reversing the effects of opioid overdose. It is particularly useful in pharmacological studies investigating opioid receptor dynamics and in the development of analytical methods for opioid detection and quantification. Naloxone-d5 serves as a critical tool for researchers studying opioid receptor interactions and opioid-related disorders. -
Opioid Receptor Blocker
β-Chlornaltrexamine dihydrochloride is a potent antagonist targeting opioid receptors, specifically effective in blocking the effects of κ-opioid receptor agonists. This compound significantly inhibits the inhibitory action on dopamine release, making it a valuable tool for investigating pain perception mechanisms. Its utilization in research provides insights into opioid signaling pathways and potential therapeutic approaches for pain management. -
Opioid Receptor
Valorphin is a peptide fragment derived from the hemoglobin β-chain (33-39) that acts as an agonist at the mu-opioid receptor. It exhibits potent analgesic properties, with an IC50 of 14 nM in binding assays. In addition to its opioid activity, Valorphin demonstrates significant anti-tumor effects, making it valuable for research in pain management and cancer biology. -
Local anesthesia/analgesic
Sameridine hydrochloride is a local anesthetic that primarily targets sodium channels to block nerve impulse transmission. It exhibits potent analgesic properties, making it effective for pain management in various clinical settings. This compound is commonly utilized in research focused on anesthetic development and pain relief mechanisms. -
Kappa-Opioid Receptor Antagonist
BU09059 is a potent and selective antagonist of the kappa-opioid receptor (KOR), displaying a pA2 value of 8.62. It exhibits nanomolar affinity specifically for the κ-receptor, demonstrating 15-fold selectivity over the μ-opioid receptor and 616-fold selectivity over the δ-opioid receptor. BU09059 effectively inhibits U50488-induced antinociception, making it a valuable tool for studying pain pathways and opioid receptor pharmacology. This compound is essential for researchers investigating the role of kappa-opioid receptors in various biological contexts. -
Analgesic Agent
α-Endorphin (human) is a neuropeptide that primarily acts on the μ-opioid receptors in the central and peripheral nervous systems. It demonstrates significant analgesic properties, making it a valuable agent in pain management research. Additionally, α-Endorphin (human) plays a role in the modulation of sexual behaviors and feelings of pleasure, further underscoring its importance in behavioral studies and neurobiology. -
Opioid Receptor Agonist
β-Endorphin (6-31) is an opioid receptor agonist that primarily targets μ-opioid receptors. This endogenous neuropeptide is produced in select neurons of both the central and peripheral nervous systems and plays a crucial role in modulating pain perception, stress responses, and maintaining homeostatic balance. Its biological activities make it a valuable reagent for research into pain management and opioid signaling pathways. -
Opioid Receptor Antagonist
TIPP is a highly selective δ-opioid receptor antagonist, exhibiting a Ki value of 1.22 nM. It effectively blocks δ-opioid receptor activity, making it a valuable tool for studying opioid signaling pathways and the effects of opioid modulation in various physiological contexts. Its unique properties facilitate research into pain management, addiction, and potential therapeutic interventions targeting the opioid system. -
Opioid Receptor Agonist
Dermorphin Analog is a synthetic heptapeptide that serves as a potent μ-opioid receptor agonist. This compound demonstrates significant analgesic activity through its high affinity for opioid receptors, making it a valuable tool for studying pain mechanisms and opioid signaling pathways. Researchers may utilize Dermorphin Analog in investigations of pain management therapies and the development of novel analgesics. -
Opioid Agonist
β-Lipotropin (60-65) is an opioid peptide that functions as a potent opioid agonist. It is known to interact with the opioid receptors, influencing pain modulation and various neurobiological processes. This reagent is valuable for research applications focused on opioid signaling pathways, pain management studies, and the exploration of its physiological roles in the body. -
δ-receptor Agonist
DSLET ([D-Ser2, Leu5, Thr6]-enkephalin) is a selective agonist of the delta-opioid receptor. This enkephalin-derived peptide exhibits high specificity for δ-receptor binding, making it a valuable tool for studying opioid signaling pathways. Its distinct activity profile supports research into pain modulation, addiction, and potential therapeutic applications in neurobiology. -
MOR Agonist
MOR agonist-5 is a selective and potent mu-opioid receptor (MOR) agonist, exhibiting an EC50 of 0.25 nM. It demonstrates a significantly lower affinity for delta-opioid receptors (DOR) with an EC50 of 10 nM, and a negligible effect on kappa-opioid receptors (KOR) and nociceptin/orphanin FQ peptide receptors (NOR) at concentrations exceeding 10,000 nM. MOR agonist-5 displays substantial antinociceptive properties, making it a valuable tool for research into pain management and opioid receptor pharmacology. -
Opioid Peptide
β-Casomorphin is an opioid peptide that primarily acts as an agonist at opioid receptors. This compound exhibits biological activity associated with pain modulation, gastrointestinal function, and is relevant in studies of addiction and opioid signaling pathways. β-Casomorphin serves as a valuable tool in pharmacological research to understand the implications of opioid peptides in various physiological processes. -
Analgesics
Azo-enkephalin is an endorphin analog that acts primarily on opioid receptors, exhibiting significant analgesic activity. This compound is utilized in the development of novel opioid analgesics, providing insight into pain modulation and therapeutic options in pain management research. Azo-enkephalin serves as a valuable tool for exploring the role of endorphins in analgesia and for studying opioid receptor interactions. -
KOR Agonist
Ketazocine is a selective κ-opioid receptor (KOR) agonist, playing a crucial role in modulating pain and sedation pathways. This compound exhibits significant analgesic and sedative properties, making it a valuable tool for research in pain management and the development of new therapeutic agents targeting the KOR. Its ability to influence opioid receptor activity can contribute to understanding KOR-related physiological processes and potential treatment strategies for pain-related disorders. -
κ-Opioid Receptor Agonist
ICI-199441 is a potent and selective κ-opioid receptor agonist, primarily involved in mediating analgesic effects. This compound has demonstrated the ability to enhance cardiac resilience in models of ischemia/reperfusion, making it a valuable tool for investigating pain modulation and cardiovascular protection. Its specificity for the κ-opioid receptor supports targeted research in pain management and heart disease. -
MOR Inhibitor
MOR agonist-1 is a selective μ-opioid receptor (MOR) agonist known for its pronounced analgesic activity. This compound is valuable for research focused on pain modulation and the exploration of pain-related disorders. Its mechanism of action makes it an essential tool for studies investigating opioid pharmacology and therapeutic interventions in pain management. -
Opioid Receptor
3,4-Difluoro-N,N-didesmethyl U-47700 TFA is a synthetic opioid compound that selectively targets opioid receptors. It exhibits potent analgesic activity, making it valuable for research into pain management and opioid receptor modulation. This compound can be utilized in studies exploring receptor binding affinity, signaling pathways, and drug formulation in opioid research. -
KOR Agonist
FEKAP is a selective kappa opioid receptor (KOR) agonist with a Ki value of 0.43 nM, demonstrating effective brain penetration. The isotope-labeled form, 11C-FEKAP, is suitable for use as a radiotracer in imaging studies targeting KOR. This compound is valuable for research applications exploring pain modulation, addiction mechanisms, and neuropharmacology. -
Opioid Receptor
2-(Di-sec-butylamino)-1-(1-(2-fluorobenzyl)-1H-pyrrol-2-yl)ethan-1-ol functions as a selective ligand for opioid receptors. This compound exhibits significant affinity and activity, making it valuable for studies on pain management and analgesic pathways. Its structural similarities to known opioids allow for exploration of the receptor interactions and potential therapeutic applications in opioid research. -
AH 7921 Metabolite
N,N-didesmethyl AH 7921 is a metabolite of the synthetic opioid AH 7921, functioning primarily as a μ-opioid receptor agonist. This compound exhibits key biological activity related to pain modulation and is utilized in research focusing on opioid metabolism and pharmacodynamics. Its analysis can contribute to understanding the metabolism and effects of opioid substances in various biological systems. -
κ-opioid agonists
ICI-204448 free acid is a potent κ-opioid agonist that demonstrates limited central nervous system penetration. It effectively displaces the binding of the kappa-opioid ligand ^3H-bremazocine from guinea pig cerebellum membranes, making it a valuable tool for exploring κ-opioid receptor interactions. This compound is useful in research applications focused on pain modulation, neuropsychiatric disorders, and the pharmacological profiling of κ-opioid receptors. -
Opioid Receptor Modulator
Opioid Receptor Modulator 1 functions as a selective modulator of opioid receptors, primarily influencing mu and delta subtypes. This compound demonstrates significant biological activity in pain relief and modulation of reward pathways, making it a valuable tool for research into analgesics and addiction therapies. Its applications extend to studies on the pharmacological effects of opioid modulation in various neurological conditions. -
Opioid Receptor Control
Isopaynantheine is an alkaloid that primarily targets opioid receptors. It demonstrates significant antinociceptive activity, making it valuable for pain management studies. Researchers utilize Isopaynantheine to explore opioid receptor modulation and its therapeutic potential in pain-related research. -
Oxycodone Metabolite
Nor-6α-Oxycodol is a metabolite of Oxycodone, classified under opioids. This compound demonstrates biological activity relevant to pain modulation and opioid receptor interaction. It serves as an important analytical tool for research focused on opioid metabolism and pharmacokinetics, providing insights into opioid effects and potential therapeutic applications. -
Opioid Receptor agonist
DuP 747 is a selective agonist of the kappa-opioid receptor. It exhibits analgesic properties, making it a valuable compound for research focused on pain management and opioid receptor pharmacology. This reagent is useful in exploring the physiological and therapeutic roles of kappa-opioid receptors in various biological contexts.
